Trial | NCT01118936  Report issue

Title

Daily Magnesium-treatment of Patients With Chronic Obstructive Pulmonary Disease
Daily Mablet-treatment of Patients With COPD

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Indication/Condition

    COPD

  • Intervention/Treatment

    magnesium hydroxide ...

  • Study Participants

    11
The present study is part of a project titled 'Magnesium in asthma and chronic obstructive pulmonary disease'. The hypothesis of the main project is that a daily magnesium supplement will benefit patients with asthma and chronic obstructive pulmonary disease.

The aim of this part of the project is to study the effect of a daily magnesium supplement for COPD-patients
Study Started
Oct 31
2010
Primary Completion
Mar 31
2013
Study Completion
Mar 31
2013
Last Update
Sep 04
2013
Estimate

Dietary Supplement Magnesium supplement (magnesium hydroxide/ -oxide)

3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS

  • Other names: Mablet

Dietary Supplement Placebo

3 tablets of placebo daily for 12 weeks

Washout No Intervention

Mablet Active Comparator

Placebo Placebo Comparator

Criteria 

Inclusion Criteria:

COPD-patients, grade moderate-severe (FEV1 30-80 % of expected. FEV1/FVC < 0,7).

Exclusion Criteria:

Se-Mg > 2,00 mmol/L, smoking cessation less than 1 year prior to study start, submission to hospital within the last two years, submission to hospital with exacerbation during the study period, major changes in eating habits within three months prior to study start and during the study period of approx.one year various conditions (e.g. gastrointestinal disease, kidney disease, pregnancy/lactation) that may affect the study results.
No Results Posted